MedLumics, a Madrid, Spain-based cardiac device company specializing in optically guided minimally invasive instruments, raised €34.4m in Series B financing.
The round was led by Edmond de Rothschild Investment Partners (EdRIP), with participation from new investors Seroba Life Sciences, Innogest Capital and a strategic investor, as well as from existing investors, Ysios Capital Partners and Caixa Capital Risc. In conjunction with the funding, EdRIP’s Olivier Litzka, Innogest’s Claudio Rumazza as well as Seroba’s James Green will join MedLumics’ board of directors.
The company intends to use the funds to advance the product and clinical development of its AblaView catheter, intended for the treatment of atrial fibrillation (AF) and other arrhythmias.
Founded in 2009 and led by Eduardo Margallo, CEO, MedLumics is an ISO13485 certified cardiology device company specializing in optically guided medical devices. Its proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling multiview optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produce high-quality real-time images.
The systems allow physicians to improve diagnostic and therapeutic procedures through a non-invasive optical evaluation of tissue.